Coherus Biosciences: Guggenheim Cuts Price Target to $10 on Q2 Earnings
By Redaktion aktie.com
This article was created with the help of artificial intelligence.
Key Takeaways
- Guggenheim analyst Paul Jeng cut the price target for Coherus Biosciences from $12 to $10 on August 7, 2026, maintaining a Buy rating.
- Coherus reported 15 percent revenue growth in Q2 2026 for its cancer drug LOQTORZI.
- The company experienced a significant decline in cash and cash equivalents and faces challenges from legacy issues from prior business activities.
- Following the divestiture of the Udenyca business, the company operates as Coherus Oncology, Inc., focusing exclusively on oncology.
- Multiple clinical data presentations from the oncology pipeline are scheduled for the second half of 2026.
Guggenheim analyst Paul Jeng cut the price target for Coherus Biosciences (NASDAQ: CHRS) from $12 to $10 on August 7, 2026, while maintaining a Buy rating. The adjustment follows the release of Q2 2026 quarterly results, which the company presented on August 5, 2026.
LOQTORZI Sales Grow 15 Percent
Coherus Biosciences, a biotech company specializing in oncology, reported 15 percent revenue growth for its cancer drug LOQTORZI in the second quarter of 2026. LOQTORZI is a biosimilar to trastuzumab, used to treat HER2-positive breast cancer and gastric cancer. The company also reported lower operating expenses following the divestiture of its Udenyca business segment, a biosimilar product supporting cancer therapy.
The earnings call on August 5, 2026 was led by Carrie Graham, Vice President of Investor Relations. Management presented progress in the oncology pipeline and announced several clinical data presentations for the second half of 2026.
Liquidity Decline and Legacy Issues Burden Balance Sheet
Despite revenue growth, Coherus is facing significant financial challenges. The company has experienced a notable decline in cash and cash equivalents. Additionally, legacy issues from prior business activities burden the balance sheet. Following the divestiture of the Udenyca business, Coherus rebranded as Coherus Oncology, Inc., to underscore its strategic focus on oncology.
Analyst Rating Remains Positive
Guggenheim maintained its Buy rating despite the price target cut. The reduction from $12 to $10 reflects a more cautious valuation while leaving room for upside potential. Analyst Paul Jeng did not publicly detail his reasoning in detail, but the revised price target remains well above the stock's current trading level.
Clinical Pipeline as Stock Driver
Coherus Biosciences emphasized upcoming clinical data presentations in its quarterly communications. The company is working on several oncology projects, with results expected in the second half of 2026. Specific details on the studies or indications were not provided in available quarterly reports. Pipeline development is considered central to the company's future valuation, following its complete shift in focus to oncology.
The divestiture of the Udenyca business has fundamentally changed Coherus' operating structure. The company now positions itself as a specialized oncology provider with a focus on biosimilars and internal development projects.